E-viri
Recenzirano
-
Hanin, Aurelie; Jimenez, Anthony D.; Gopaul, Margaret; Asbell, Hannah; Aydemir, Seyhmus; Basha, Maysaa Merhi; Batra, Ayush; Damien, Charlotte; Day, Gregory S.; Eka, Onome; Eschbach, Krista; Fatima, Safoora; Fields, Madeline C.; Foreman, Brandon; Gerard, Elizabeth E.; Gofton, Teneille E.; Haider, Hiba A.; Hantus, Stephen T.; Hocker, Sara; Jongeling, Amy; Kalkach Aparicio, Mariel; Kandula, Padmaja; Kang, Peter; Kazazian, Karnig; Kellogg, Marissa A.; Kim, Minjee; Lee, Jong Woo; Marcuse, Lara V.; McGraw, Christopher M.; Mohamed, Wazim; Orozco, Janet; Pimentel, Cederic M.; Punia, Vineet; Ramirez, Alexandra M.; Steriade, Claude; Struck, Aaron F.; Taraschenko, Olga; Treister, Andrew K.; Wainwright, Mark S.; Yoo, Ji Yeoun; Zafar, Sahar; Zhou, Daniel J.; Zutshi, Deepti; Gaspard, Nicolas; Hirsch, Lawrence J.
Epilepsia (Copenhagen), 06/2024Journal Article
Abstract In response to the evolving treatment landscape for new‐onset refractory status epilepticus (NORSE) and the publication of consensus recommendations in 2022, we conducted a comparative analysis of NORSE management over time. Seventy‐seven patients were enrolled by 32 centers, from July 2016 to August 2023, in the NORSE/FIRES biorepository at Yale. Immunotherapy was administered to 88% of patients after a median of 3 days, with 52% receiving second‐line immunotherapy after a median of 12 days (anakinra 29%, rituximab 25%, and tocilizumab 19%). There was an increase in the use of second‐line immunotherapies (odds ratio OR = 1.4, 95% CI = 1.1–1.8) and ketogenic diet (OR = 1.8, 95% CI = 1.3–2.6) over time. Specifically, patients from 2022 to 2023 more frequently received second‐line immunotherapy (69% vs 40%; OR = 3.3; 95% CI = 1.3–8.9)—particularly anakinra (50% vs 13%; OR = 6.5; 95% CI = 2.3–21.0), and the ketogenic diet (OR = 6.8; 95% CI = 2.5–20.1)—than those before 2022. Among the 27 patients who received anakinra and/or tocilizumab, earlier administration after status epilepticus onset correlated with a shorter duration of status epilepticus ( ρ = .519, p = .005). Our findings indicate an evolution in NORSE management, emphasizing the increasing use of second‐line immunotherapies and the ketogenic diet. Future research will clarify the impact of these treatments and their timing on patient outcomes.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.